Back to mobile site

BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO)

October 11, 2024 7:01 AM EDT Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $12.00 price target on Sutro Biopharma (NASDAQ: STRO).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login